Mulakan
AlenCiken

$PRQR Announces Positive Results from Clinical Trial of QR-421a

ProQR Therapeutics N.V. (NASDAQ:PRQR)  
AlenCiken Telah dikemas kini   
NASDAQ:PRQR   ProQR Therapeutics N.V.
Trend Analysis Chart Patterns Fundamental Analysis biotech biotechnology biotechstocks biotechs biotechstock biotehnology
1
0
trendanalysis chartpattern fundamental biotech biotechnology biotechstocks biotechs biotechstock biotehnology
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.

QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)

QR-421a observed to be well tolerated with no serious adverse events reported

Two pivotal Phase 2/3 trials are expected to start by the end of 2021

finance.yahoo.com/ne...nical-110000726.html
Komen:
Citigroup Reiterated buy $33 → $44
Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.